Watchlist Price Alert

Viridian Therapeutics Inc... (VRDN)

NASDAQ: VRDN · Real-Time Price · USD

12.84

-0.28 (-2.13%)

At close: May 13, 2025, 3:59 PM

12.81

-0.19%

After-hours: May 13, 2025, 04:20 PM EDT

-2.13% (1D)

Bid	12
Market Cap	1.05B
Revenue (ttm)	302K
Net Income (ttm)	-269.95M
EPS (ttm)	-3.35
PE Ratio (ttm)	-3.83
Forward PE	-3.13
Analyst	Buy

Ask	13.6
Volume	658,831
Avg. Volume (20D)	926,646
Open	13.16
Previous Close	13.12
Day's Range	12.60 - 13.13
52-Week Range	9.90 - 27.20
Beta	0.62

About VRDN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VRDN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Viridian Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $72K exceeds estimates by $27.92K, with 0.00% YoY growth.

EPS of -0.87 exceeds estimates by 0.09, with -10.13% YoY decline.

Why Price Moved

4 months ago

+20.67%

Viridian Therapeutics shares are trading higher af... Unlock content with Pro Subscription

7 months ago

+7.76%

Viridian Therapeutics shares are trading higher after BTIG raised its price target on the stock from $56 to $61.

News

6 days ago · businesswire.com

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

1 week ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.79 per share a year ago.

1 week ago · businesswire.com

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...

1 week ago · businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago · businesswire.com

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

2 months ago · seekingalpha.com

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...

2 months ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.